Breaking Finance News

Northland Capital reiterated Beximco Pharmaceuticals Ltd (LON:BXP) to Corporate in a report released today.

Just yesterday Beximco Pharmaceuticals Ltd (LON:BXP) traded 0.00% even at 62.50GBX. Beximco Pharmaceuticals Ltd’s 50-day moving average is 62.14GBX and its 200-day moving average is 63.35GBX. The last closing price is down -6.87% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 224,654 shares of the stock were exchanged, up from an average trading volume of 39,045

Northland Capital has reiterated Beximco Pharmaceuticals Ltd (LON:BXP) to Corporate in a report released on 11/14/2017.

See Chart Below

Beximco Pharmaceuticals Ltd (LON:BXP)

Beximco Pharmaceuticals Ltd has a 52 week low of 36.45GBX and a 52 week high of 71.75GBX Beximco Pharmaceuticals Ltd’s market capitalization is presently 0 GBX.

A total of 1 brokerage has released a report on Beximco Pharmaceuticals Ltd. zero brokerages rating the company a strong buy, zero brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of 41.00GBX.

General Company Details For Beximco Pharmaceuticals Ltd (LON:BXP)

Beximco Pharmaceuticals Limited (BPL) is engaged in the manufacturing and marketing of generic pharmaceuticals formulation products, including intravenous fluids and active pharmaceutical ingredients (APIs). The Company also provides contract manufacturing services. The Company produces approximately 300 generic medicines, which are available in over 500 different presentations and the portfolio encompasses various key therapeutic categories, including antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology and gastrointestinal. Its product categories also include anti-infectives, musculoskeletal, oncology, respiratory, skin care, vitamins and minerals supplement, and others. The Company's products include Acifix, Femzole, Q-Rash, Tamona, Taverin, Tobasol, IcyKool Cream, Intracef, Gastalfet, Iprasol, Calorate, Gentosep and others. BPL's products are sold in domestic and international markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *